You searched for "incontinence"
Guide to gaining approval for a clinical study
This article focuses on gaining approval for clinical research involving NHS patients, although the principles can be applied to other types of research. It can be quite a daunting process for the uninitiated applicant. Often it can be made less...
The cost of bladder cancer: what can be done?
The rising cost of cancer care is a growing concern for health systems. A 2020 study estimated Europe’s annual cancer-related expenditure at €199 billion, with €109 billion attributed to healthcare costs. Bladder cancer (BC), in particular, imposes a significant financial...The Future of Prostate Cancer Imaging: What News: Webinar
This session will explore how artificial intelligence (AI) is reshaping prostate cancer imaging from MRI diagnostics to treatment planning and what it means for your clinical practice. Featured Speakers Include: • David Bazaga, VP of Product, Quibim ‘The role of...Potassium citrate in urolithiasis
Kidney stone disease (KSD) is increasing in prevalence globally, with those affected often requiring hospitalisation, diagnostic imaging and intervention [1,2]. The incidences of KSD varies according to several factors including genetics, geographical location, climate, diet and ethnicity [3]. Stone recurrence...Elements of AI
Given that a recent issue of Urology News focused on artificial intelligence (AI) in urology and potential problems it might bring, this month’s digital review focuses on a free course in artificial intelligence. Elements of AI (www.elementsofai.com) is a free...Ketamine-Induced Uropathy: Emerging Challenges and Effective Interventions
Ketamine‑induced uropathy (KIU) has rapidly become one of the most urgent and complex bladder health challenges facing clinicians across the UK. With cases rising sharply among young people and frontline services under increasing pressure, our Bladder Health UK study day...Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...Artificial intelligence in bladder cancer diagnostics
Bladder cancer (BCa), ranking as the 10th most common cancer worldwide, poses a significant health burden with high morbidity and mortality [1]. Timely tumour detection and accurate evaluation are crucial for effective management, as the prognosis is dependent on the...
